Otonomy, Inc. Logo
Otonomy to Participate in Four Upcoming Investor Conferences
September 02, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 16:22 ET | Otonomy, Inc.
Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patientsPublic offering completed for total gross proceeds of $69.1 millionResults from Phase 3 trial of OTIVIDEX® in...
Otonomy, Inc. Logo
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
August 03, 2020 07:30 ET | Otonomy, Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 28, 2020 16:05 ET | Otonomy, Inc.
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 13, 2020 16:01 ET | Otonomy, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Pricing of $60.1 Million Public Offering
July 09, 2020 09:00 ET | Otonomy, Inc.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Proposed Public Offering
July 08, 2020 16:03 ET | Otonomy, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
July 06, 2020 16:04 ET | Otonomy, Inc.
OTO-313 demonstrated a higher proportion of responders than placeboGiven clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitusOTO-313...
Otonomy, Inc. Logo
Otonomy Provides Update on OTIVIDEX® Program
July 06, 2020 16:02 ET | Otonomy, Inc.
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an...
Otonomy, Inc. Logo
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 16:05 ET | Otonomy, Inc.
Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...